Key facts
- It has raised $3.5M; the latest was Later Stage VC ($3.5M) in Mar 2026.
- Notable investors include Demcon, Myosotis Investments.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Scinus Cell Expansion
- ·The full record, as it builds
Funding rounds
No funding rounds for Scinus Cell Expansion are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Scinus Cell Expansion
Developer of stem cell cultivation bioreactor technology intended to make cell therapies accessible globally. The company offers a bioreactor platform that enables clinical-scale cell 3D cultivation in a controlled environment and provides an alternative to 2D cell growth in tissue culture flasks or cell stacks, along with process optimization and translation consulting services, enabling medical institutions to cultivate stem cells in a controlled and efficient way.
- Sector
- Healthcare
- HQ
- Zeist, Netherlands
- Founded
- 2016
- Employees
- 10
- Website
- scinus.com/
- Ownership
- Privately Held (backing)
Scinus Cell Expansion doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Scinus Cell Expansion shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Scinus Cell Expansion in its N-PORT filings yet. We sweep new filings monthly.